TY - JOUR T1 - DeepOS: pan-cancer prognosis estimation from RNA-sequencing data JF - medRxiv DO - 10.1101/2021.07.10.21260300 SP - 2021.07.10.21260300 AU - M. Pavageau AU - L. Rebaud AU - D. Morel AU - S. Christodoulidis AU - E. Deutsch AU - C. Massard AU - H. Vanacker AU - L. Verlingue Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/14/2021.07.10.21260300.abstract N2 - RNA-sequencing (RNA-seq) analysis offers a tumor-centered approach of growing interest for personalizing cancer care. However, existing methods – including deep learning models – struggle to reach satisfying performances on survival prediction based upon pan-cancer RNA-seq data. Here, we present DeepOS, a novel deep learning model that predicts overall survival (OS) from pan-cancer RNA-seq with a concordance-index of 0.715 and a survival AUC of 0.752 across 33 TCGA tumor types whilst tested on an unseen test cohort. DeepOS notably uses (i) prior biological knowledge to condense inputs dimensionality, (ii) transfer learning to enlarge its training capacity through pre-training on organ prediction, and (iii) mean squared error adapted to survival loss function; all of which contributed to improve the model performances. Interpretation showed that DeepOS learned biologically-relevant prognosis biomarkers. Altogether, DeepOS achieved unprecedented and consistent performances on pan-cancer prognosis estimation from individual RNA-seq data.Competing Interest StatementLV reports personal fees from Adaptherapy, non-personal fees from Pierre-Fabre and Servier, grants from Bristol-Myers Squibb, all outside the submitted work. As part of the Drug Development Department (DITEP), LV, CM, ED report being: Principal/sub-Investigator of Clinical Trials for Abbvie, Adaptimmune, Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex Pharmaceuticals, Astra Zeneca Ab, Aveo, Basilea Pharmaceutica International Ltd, Bayer Healthcare Ag, Bbb Technologies Bv, Beigene, Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Ca, Celgene Corporation, Chugai Pharmaceutical Co, Clovis Oncology, Cullinan-Apollo, Daiichi Sankyo, Debiopharm, Eisai, Eisai Limited, Eli Lilly, Exelixis, Faron Pharmaceuticals Ltd, Forma Tharapeutics, Gamamabs, Genentech, Glaxosmithkline, H3 Biomedicine, Hoffmann La Roche Ag, Imcheck Therapeutics, Innate Pharma, Institut De Recherche Pierre Fabre, Iris Servier, Janssen Cilag, Janssen Research Foundation, Kura Oncology, Kyowa Kirin Pharm. Dev, Lilly France, Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Molecular Partners Ag, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology Nv, Oncoethix, Oncopeptides, Orion Pharma, Ose Pharma, Pfizer, Pharma Mar, Pierre Fabre, Medicament, Roche, Sanofi Aventis, Seattle Genetics, Sotio A.S, Syros Pharmaceuticals, Taiho Pharma, Tesaro, Xencor. Research Grants from Astrazeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Onxeo, Pfizer, Roche, Sanofi. Non-financial support (drug supplied) from Astrazeneca, Bayer, BMS, Boringher Ingelheim, Medimmune, Merck, NH TherAGuiX, Onxeo, Pfizer, Roche. Other authors have no conflict of interest to declare.Funding StatementThis project has been funded in part by ARC foundation for cancer research: Fondation ARC pour la recherche clinique, 9 rue Guy Moquet 94803 Villejuif, France. Grant number SIGNIT201901302.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Only public data have been usedAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe code to load and preprocess the data, together with the code to build, train and test the model is publically available on www.github.com/DITEP/DeepOS. The preprocessed data, ready to be inputted in the model, is also publically available for maximum transparency. https://jhubiostatistics.shinyapps.io/recount/ https://www.github.com/DITEP/DeepOS ER -